Kairos Pharma to Host Virtual KOL Event Discussing Interim Efficacy Results of ENV105 in Advanced Prostate Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2025
0mins
Source: Newsfilter
KOL Event Announcement: Kairos Pharma will host a KOL event on September 18 to discuss interim efficacy results from a Phase 2 trial of ENV105 for advanced prostate cancer, featuring insights from leading experts in oncology.
Trial Safety Results: The interim safety analysis showed that ENV105, combined with apalutamide, was well tolerated with no significant toxicities reported, addressing the growing need for effective treatments in castration-resistant prostate cancer.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on KAPA
Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.675
Low
4.00
Averages
4.00
High
4.00
Current: 0.675
Low
4.00
Averages
4.00
High
4.00
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
Continue Reading
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.
Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.
Continue Reading